Recent advances in intestinal fibrosis

Mol Aspects Med. 2024 Apr:96:101251. doi: 10.1016/j.mam.2024.101251. Epub 2024 Feb 14.

Abstract

Despite many progresses have been made in the treatment of inflammatory bowel disease, especially due to the increasing number of effective therapies, the development of tissue fibrosis is a very common occurrence along the natural history of this condition. To a certain extent, fibrogenesis is a physiological and necessary process in all those conditions characterised by chronic inflammation. However, the excessive deposition of extracellular matrix within the bowel wall will end up in the formation of strictures, with the consequent need for surgery. A number of mechanisms have been described in this process, but some of them are not yet clear. For sure, the main trigger is the presence of a persistent inflammatory status within the mucosa, which in turn favours the occurrence of a pro-fibrogenic environment. Among the main key players, myofibroblasts, fibroblasts, immune cells, growth factors and cytokines must be mentioned. Although there are no available therapies able to target fibrosis, the only way to prevent it is by controlling inflammation. In this review, we summarize the state of art of the mechanisms involved in gut fibrogenesis, how to diagnose it, and which potential targets could be druggable to tackle fibrosis.

Keywords: Collagen; Crohn's disease; Extracellular matrix; Myofibroblast; Strictureplasty; Ulcerative colitis.

Publication types

  • Review

MeSH terms

  • Crohn Disease* / metabolism
  • Crohn Disease* / pathology
  • Fibroblasts / metabolism
  • Fibrosis
  • Humans
  • Inflammation / metabolism
  • Intestines